Abstract
In real world data (RWD) studies, observed datasets are often subject to left truncation, which can bias estimates of survival parameters. Standard methods can only suitably account for left truncation when survival and entry time are independent. Therefore, in the dependent left truncation setting, it is important to quantify the magnitude and direction of estimator bias to determine whether an analysis provides valid results. We conduct simulation studies of common RWD analytic settings in order to determine when standard analysis provides reliable estimates, and to identify factors that contribute most to estimator bias. We also outline a procedure for conducting a simulation-based sensitivity analysis for an arbitrary dataset subject to dependent left truncation. Our simulation results show that when comparing a truncated real-world arm to a non-truncated arm, we observe the estimated hazard ratio biased upwards, providing conservative inference. The most important data-generating parameter contributing to bias is the proportion of left truncated patients, given any level of dependence between survival and entry time. For specific datasets and analyses that may differ from our example, we recommend applying our sensitivity analysis approach to determine how results would change given varying proportions of truncation.
Competing Interest Statement
At the time of the study, all authors report employment in Flatiron Health, Inc., an independent subsidiary of Roche. All authors report stock ownership in Roche.
Funding Statement
This study was sponsored by Flatiron Health, which is an independent subsidiary of the Roche Group
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Institutional Review Board (WCG IRB) approval of the study protocol was obtained prior to study conduct, and included a waiver of informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Competing interests:
Disclosures: At the time of the study, all authors report employment in Flatiron Health, Inc., an independent subsidiary of Roche. All authors report stock ownership in Roche.
Funding: This study was sponsored by Flatiron Health, which is an independent subsidiary of the Roche Group.
Specific points in the text of the introduction, results and discussion.
Data Availability
The data that support the findings of this study have been originated by Flatiron Health, Inc. These de-identified data may be made available upon request, and are subject to a license agreement with Flatiron Health; interested researchers should contact <DataAccess{at}flatiron.com> to determine licensing terms
